Literature DB >> 25614162

Age-adjusted high-sensitivity troponin T cut-off value for risk stratification of pulmonary embolism.

Anja Kaeberich1, Valerie Seeber1, David Jiménez2, Maciej Kostrubiec3, Claudia Dellas4, Gerd Hasenfuß5, Evangelos Giannitsis6, Piotr Pruszczyk3, Stavros Konstantinides1, Mareike Lankeit7.   

Abstract

High-sensitivity troponin T (hsTnT) helps in identifying pulmonary embolism patients at low risk of an adverse outcome. In 682 normotensive pulmonary embolism patients we investigate whether an optimised hsTnT cut-off value and adjustment for age improve the identification of patients at elevated risk. Overall, 25 (3.7%) patients had an adverse 30-day outcome. The established hsTnT cut-off value of 14 pg·mL(-1) retained its high prognostic value (OR (95% CI) 16.64 (2.24-123.74); p=0.006) compared with the cut-off value of 33 pg·mL(-1) calculated by receiver operating characteristic analysis (7.14 (2.64-19.26); p<0.001). In elderly (aged ≥75 years) patients, an age-optimised hsTnT cut-off value of 45 pg·mL(-1) but not the established cut-off value of 14 pg·mL(-1) predicted an adverse outcome. An age-adjusted hsTnT cut-off value (≥14 pg·mL(-1) for patients aged <75 years and ≥45 pg·mL(-1) for patients aged ≥75 years) provided additive and independent prognostic information on top of the simplified pulmonary embolism severity index (sPESI) and echocardiography (OR 4.56 (1.30-16.01); p=0.018, C-index=0.77). A three-step approach based on the sPESI, hsTnT and echocardiography identified 16.6% of all patients as being at higher risk (12.4% adverse outcome). Risk assessment of normotensive pulmonary embolism patients was improved by the introduction of an age-adjusted hsTnT cut-off value. A three-step approach helped identify patients at higher risk of an adverse outcome who might benefit from advanced therapy.
Copyright ©ERS 2015.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25614162     DOI: 10.1183/09031936.00174514

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  6 in total

1.  An evaluation of peri-operative clinical, serological and radiological parameters in hip arthroplasties -a prospective observational study of Indian cohorts.

Authors:  Atul Panghate; Abhinav D Jogani; Sameer Panchal; Jigar Desai; Nandan Marathe; Rajkumar Rathod
Journal:  J Orthop       Date:  2022-02-17

Review 2.  Cardiac Biomarkers in Patients with Acute Pulmonary Embolism.

Authors:  Luc Janisset; Maxime Castan; Géraldine Poenou; Raphael Lachand; Patrick Mismetti; Alain Viallon; Laurent Bertoletti
Journal:  Medicina (Kaunas)       Date:  2022-04-14       Impact factor: 2.948

Review 3.  Risk Stratification in Patients with Acute Pulmonary Embolism: Current Evidence and Perspectives.

Authors:  Antonio Leidi; Stijn Bex; Marc Righini; Amandine Berner; Olivier Grosgurin; Christophe Marti
Journal:  J Clin Med       Date:  2022-04-30       Impact factor: 4.964

4.  ANMCO Position Paper: the use of non-vitamin K dependent new oral anticoagulant(s) in pulmonary embolism therapy and prevention.

Authors:  Iolanda Enea; Loris Roncon; Michele Massimo Gulizia; Michele Azzarito; Cecilia Becattini; Amedeo Bongarzoni; Franco Casazza; Claudio Cuccia; Carlo D'Agostino; Matteo Rugolotto; Marco Vatrano; Eugenio Vinci; Paride Fenaroli; Dario Formigli; Paolo Silvestri; Federico Nardi; Maria Cristina Vedovati; Marino Scherillo
Journal:  Eur Heart J Suppl       Date:  2017-05-02       Impact factor: 1.803

5.  Evaluation of Serum Des-Gamma-Carboxy Prothrombin for the Diagnosis of Hepatitis B Virus-Related Hepatocellular Carcinoma: A Meta-Analysis.

Authors:  Jiu Chen; Guolin Wu; Youdi Li
Journal:  Dis Markers       Date:  2018-10-04       Impact factor: 3.434

6.  Rapid prediction of adverse outcomes for acute normotensive pulmonary embolism: derivation of the Calgary Acute Pulmonary Embolism score.

Authors:  Kevin Solverson; Christopher Humphreys; Zhiying Liang; Graeme Prosperi-Porta; James E Andruchow; Paul Boiteau; Andre Ferland; Eric Herget; Doug Helmersen; Jason Weatherald
Journal:  ERJ Open Res       Date:  2021-04-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.